Un nouvel ouvrage examine le potentiel des champignons hallucinogènes pour traiter le trouble obsessionnel-compulsif, souvent qualifié de « trouble du doute ».
L'extrait décrit une scène à New York où Adam Strauss hésite entre deux lecteurs MP3 tout en tenant le fil de ses écouteurs. Il s'appuie sur l'idée que le TOC est une forme d'incertitude et s'interroge sur la capacité de la psilocybine à réduire ce doute.
A placebo-controlled trial has shown that a single dose of psilocybin, the active ingredient in magic mushrooms, leads to rapid and lasting reductions in obsessive-compulsive disorder symptoms among treatment-resistant patients. The effects persisted for at least 12 weeks in participants who had not responded to conventional therapies. Researchers highlight the potential of this psychedelic for mental health treatment, though larger studies are needed.
Rapporté par l'IA
President Donald Trump signed an executive order on Saturday directing federal agencies to accelerate access to psychedelic drugs like psilocybin and ibogaine for treating mental health conditions, including depression, anxiety, and PTSD. The order allocates $50 million in funding and instructs the FDA to prioritize reviews. Trump was joined by Health and Human Services Secretary Robert F. Kennedy Jr., Dr. Mehmet Oz, former Navy SEAL Marcus Luttrell, and podcast host Joe Rogan.
Science journalist Michaeleen Doucleff appeared on CBS Saturday Morning to discuss her new book, Dopamine Kids. She offered advice for parents aiming to reduce their children's screen time and junk food consumption. The discussion highlights practical strategies rooted in scientific insights.
Rapporté par l'IA
A randomized clinical trial found that 24 minutes of specially designed music paired with auditory beat stimulation significantly lowers anxiety symptoms. Researchers at Toronto Metropolitan University tested various listening durations on 144 adults with moderate anxiety. The 24-minute session provided the strongest benefits.